US20030119151A1 - Process for the preparation of D-pantothenic acid and/or salts thereof - Google Patents

Process for the preparation of D-pantothenic acid and/or salts thereof Download PDF

Info

Publication number
US20030119151A1
US20030119151A1 US10/167,647 US16764702A US2003119151A1 US 20030119151 A1 US20030119151 A1 US 20030119151A1 US 16764702 A US16764702 A US 16764702A US 2003119151 A1 US2003119151 A1 US 2003119151A1
Authority
US
United States
Prior art keywords
gene
process according
codes
pantothenic acid
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/167,647
Other languages
English (en)
Inventor
Thomas Hermann
Birgit Witteck
Mechthild Rieping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Assigned to DEGUSSA AS reassignment DEGUSSA AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WITTECK, BIRGIT, HERMANN, THOMAS, RIEPING, MECHTHILD
Assigned to DEGUSSA AG reassignment DEGUSSA AG CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME. DOCUMENT PREVIOUSLY RECORDED AT REEL 013370 FRAME 0345. Assignors: WITTECK, BIRGIT, HERMANN, THOMAS, RIEPING, MECHTHILD
Publication of US20030119151A1 publication Critical patent/US20030119151A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins

Definitions

  • the present invention relates to a process for the preparation of D-pantothenic acid and salts thereof or mixtures comprising these compounds using microorganisms of the Enterobacteriaceae family in which at least the hns gene is enhanced.
  • Pantothenic acid is produced worldwide in an order of magnitude of several thousand tons a year. It is used inter alia in human medicine, in the pharmaceuticals industry and in the foodstuffs industry. A large portion of the pantothenic acid produced is used for nutrition of stock animals such as poultry and pigs.
  • Pantothenic acid can be prepared by chemical synthesis, or biotechnologically by fermentation of suitable microorganisms in suitable nutrient solutions.
  • chemical synthesis DL-pantolactone is an important precursor. It is prepared in a multi-stage process from formaldehyde, isobutylaldehyde and cyanide, and in further process steps, the racemic mixture is separated, D-pantolactone is subjected to a condensation reaction with ⁇ -alanine, and D-pantothenic acid is obtained in this way.
  • the typical commercial form is the calcium salt of D-pantothenic acid.
  • the calcium salt of the racemic mixture of D,L-pantothenic acid is also customary.
  • the advantage of the fermentative preparation by microorganisms lies in the direct formation of the desired stereoisomeric form, that is to say the D-form, which is free from L-pantothenic acid.
  • E. coli Escherichia coli
  • Arthrobacter ureafaciens can produce D-pantothenic acid in a nutrient solution which comprises glucose, DL-pantoic acid and ⁇ -alanine, as shown in EP-A 0 493 060.
  • EP-A 0 493 060 furthermore shows that in the case of E. coli, the formation of D-pantothenic acid is improved by amplification of pantothenic acid biosynthesis genes from E. coli which are contained on the plasmids pFV3 and pFV5 in a nutrient solution comprising glucose, DL-pantoic acid and ⁇ -alanine.
  • EP-A 0 590 857 and U.S. Pat. No. 5,518,906 describe mutants derived from E. coli strain IFO3547, such as FV5714, FV525, FV814, FV521, FV221, FV6051 and FV5069, which carry resistances to various antimetabolites, such as salicylic acid, ⁇ -ketobutyric acid, ⁇ -hydroxyaspartic acid, O-methylthreonine and ⁇ -ketoisovaleric acid. They produce pantoic acid in a nutrient solution comprising glucose, and D-pantothenic acid in a nutrient solution comprising glucose and ⁇ -alanine.
  • panB, panC and panD which are said to be contained on the plasmid pFV31, in the above-mentioned strains the production of D-pantoic acid in nutrient solutions comprising glucose and the production of D-pantothenic acid in a nutrient solution comprising glucose and ⁇ -alanine is improved.
  • WO 97/10340 furthermore reports on the favorable effect of the enhancement of the ilvGM operon on the production of D-pantothenic acid.
  • EP-A-1001027 reports on the effect of the enhancement of the panE gene on the formation of D-pantothenic acid.
  • the D-pantothenic acid or the corresponding salt is isolated from the fermentation broth and purified (EP-A-0590857 and WO 96/33283) and used accordingly in purified form, or the fermentation broth comprising D-pantothenic acid is dried in total (EP-A-1050219) and used in particular as a feedstuffs additive.
  • the invention provides a process for the preparation of D-pantothenic acid and/or salts thereof using microorganisms of the Enterobacteriaceae family which in particular already produce D-pantothenic acid and in which at least one, preferably endogenous nucleotide sequence(s) which code(s) for the hns gene is enhanced, in particular over-expressed.
  • the gene which codes for the DNA-binding protein HLP-II and optionally alleles of this gene are enhanced, in particular over-expressed, under conditions suitable for the formation of the gene product;
  • pantothenic acid biosynthesis pathway further genes of the pantothenic acid biosynthesis pathway are optionally attenuated or enhanced at the same time in order to increase the production of pantothenic acid;
  • the fermentation is optionally carried out in the presence of alkaline earth metal compounds, these being added to the fermentation broth continuously or discontinuously in preferably stoichiometric amounts;
  • the invention also provides a process in which, after conclusion of the fermentation, some or all ( ⁇ 0 to 100%) of the biomass remains in the fermentation broth, and the broth obtained in this way is processed, optionally after concentration, to a solid mixture which comprises D-pantothenic acid and/or salts thereof and preferably comprises further constituents from the fermentation broth.
  • FIG. 1 Map of the plasmid pTrc99Ahns containing the hns gene.
  • the length data are to be understood as approx. data.
  • the abbreviations and designations used have the following meaning:
  • lacI Gene for the repressor protein of the trc promoter
  • hns Coding region of the hns gene
  • rrnBT rRNA terminator region
  • HindIII Restriction endonuclease from Haemophilus influenzae R d
  • XbaI Restriction endonuclease from Xanthomonas campestris
  • HpaI Restriction endonuclease from Haemophilus parainfluenzae
  • StyI Restriction endonuclease from Salmonella typhi
  • D-pantothenic acid or pantothenic acid or pantothenate are mentioned herein, this means not only the free acids but also the salts of D-pantothenic acid, such as e.g. the calcium, sodium, ammonium or potassium salt.
  • Endogenous genes or “endogenous nucleotide sequences” are understood as meaning the genes or nucleotide sequences present in the population of a species.
  • the term “enhancement” in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, of the ORF (Open Reading Frame) or ORFs, using a potent promoter or a gene or allele or ORF which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.
  • ORF Open Reading Frame
  • the activity or concentration of the corresponding enzyme or protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or wild-type enzyme or the activity or concentration of the protein or enzyme in the starting microorganism.
  • the microorganisms which the present invention provides can produce D-pantothenic acid from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They are representatives of Enterobacteriaceae, in particular of the genus Escherichia. Of the genus Escherichia, the specie Escherichia coli is to be mentioned in particular. Within the species Escherichia coli the so-called K-12 strains, such as e. g. the strains MG1655 or W3110 (Neidhard et al.: Escherichia coli and Salmonella.
  • Suitable D-pantothenic acid-producing strains of the genus Escherichia, in particular of the species Escherichia coli are, for example
  • Enterobacteriaceae produce D-pantothenic acid in an improved manner after enhancement, in particular over-expression of the hns gene.
  • the use of endogenous genes is preferred.
  • DNA-binding protein HLP-II (HU, BH2, HD, NS); pleiotropic regulator
  • the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated.
  • Expression cassettes which are incorporated upstream of the structural gene act in the same way.
  • inducible promoters it is additionally possible to increase the expression in the course of fermentative D-pantothenic acid production.
  • the expression is likewise improved by measures to prolong the life of the m-RNA.
  • the enzyme activity is also increased by preventing the degradation of the enzyme protein.
  • the genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome.
  • an over-expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
  • Plasmid vectors which are capable of replication in Enterobacteriaceae such as e.g. cloning vectors derived from pACYC184 (Bartolomé et al.; Gene 102, 75-78 (1991)), pTrc99A (Amann et al.; (Gene 69:301-315 (1988)) or pSC101 derivatives (Vocke and Bastia, Proceedings of the National Academy of Science USA 80 (21):6557-6561 (1983)) can be used.
  • a strain transformed with one or more plasmid vectors where the plasmid vector(s) carries at least one nucleotide sequence which codes for the hns gene can be employed in a process according to the invention.
  • panB gene which codes for ketopantoate hydroxymethyl transferase (U.S. Pat. No. 5,518,906)
  • panE gene which codes for ketopantoate reductase (EP-A-1001027)
  • panD gene which codes for aspartate decarboxylase (U.S. Pat. No. 5,518,906)
  • panC gene which codes for pantothenate synthetase (U.S. Pat. No. 5,518,906)
  • aldH gene which codes for NADP-dependent aldehyde dehydrogenase (Heim and Strehler, Gene 99:15-23 (1991)) and
  • the term “attenuation” in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme or protein with a low activity or inactivates the corresponding gene or enzyme (protein), and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
  • D-pantothenic acid In addition to over-expression of the hns gene it may furthermore be advantageous for the production of D-pantothenic acid to eliminate undesirable side reactions (Nakayama: “Breeding of Amino Acid Producing Microorganisms”, in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982). Bacteria in which the metabolic pathways which reduce the formation of D-pantothenic acid are at least partly eliminated can be employed in the process according to the invention.
  • the microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch (feed process) or the repeated fed batch process (repetitive feed process).
  • batch culture the fed batch
  • feed process the fed batch
  • repeated fed batch process repeative feed process.
  • a summary of known culture methods is described in the textbook by Chmiel (Bioreatechnik 1. Einf ⁇ fraction (u) ⁇ hrung in die Biovonstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere saw [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
  • the culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook “Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D.C., USA, 1981).
  • Sugars and carbohydrates such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
  • Organic nitrogen-containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea
  • inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen.
  • the sources of nitrogen can be used individually or as a mixture.
  • Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus.
  • the culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth.
  • essential growth substances such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.
  • Precursors of pantothenic acid, such as aspartate, ⁇ -alanine, ketoisovalerate, ketopantoic acid or pantoic acid and optionally salts thereof, can moreover be added to the culture medium.
  • the starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.
  • Basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture.
  • alkaline earth metal salts of pantothenic acid in particular the calcium salt or magnesium salt
  • an inorganic compound containing an alkaline earth metal such as, for example, calcium hydroxide or MgO
  • an organic compound such as the alkaline earth metal salt of an organic acid, for example calcium acetate
  • the cation necessary for preparation of the desired alkaline earth metal salt of D-pantothenic acid is introduced into the fermentation broth directly in the desired amount, preferably in an amount of 0.95 to 1.1 equivalents.
  • the salts can also be formed after conclusion of the fermentation by addition of the inorganic or organic compounds to the fermentation broth, from which the biomass has optionally been removed beforehand.
  • Antifoams such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added to the medium to maintain the stability of plasmids.
  • oxygen or oxygen-containing gas mixtures such as e.g. air, are introduced into the culture.
  • the temperature of the culture is usually 25° C. to 45° C., and preferably 30° C. to 40° C.
  • the pH is in general between 5.0 to 8.0, preferably 5.5 to 7.6.
  • the fermentation is continued until a maximum of D-pantothenic acid has formed. This target is usually reached within 10 hours to 160 hours.
  • the D-pantothenic acid or the corresponding salts of D-pantothenic acid contained in the fermentation broth can then be isolated and purified in accordance with known procedures.
  • the fermentation broths comprising D-pantothenic acid and/or salts thereof preferably first to be freed from all or some of the biomass by known separation methods, such as, for example, centrifugation, filtration, decanting or a combination thereof.
  • separation methods such as, for example, centrifugation, filtration, decanting or a combination thereof.
  • the biomass in its entirety in the fermentation broth.
  • the suspension or solution is preferably concentrated and then worked up to a powder, for example with the aid of a spray dryer or a freeze-drying unit.
  • This powder is then in general converted by suitable compacting or granulating processes, e. g. also build-up granulation, into a coarser-grained, free-flowing, storable and largely dust-free product with a particle size distribution of preferably 20 to 2000 ⁇ m, in particular 100 to 1400 ⁇ m.
  • suitable compacting or granulating processes e. g. also build-up granulation, into a coarser-grained, free-flowing, storable and largely dust-free product with a particle size distribution of preferably 20 to 2000 ⁇ m, in particular 100 to 1400 ⁇ m.
  • organic or inorganic auxiliary substances or carriers such as starch, gelatine, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.
  • the fermentation product with or without further of the conventional fermentation constituents, can be absorbed, in particular sprayed, on to an organic or inorganic carrier substance which is known and conventional in feedstuffs processing, such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or stabilized with conventional thickeners or binders.
  • feedstuffs processing such as, for example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or stabilized with conventional thickeners or binders.
  • mixtures comprising the carrier substances can also be processed to a product with the desired particle size distribution by granulation processes.
  • D-Pantothenic acid and/or the desired salt of D-pantothenic acid or a formulation comprising these compounds is optionally added in a suitable process stage during or after the fermentation in order to achieve or establish the content of pantothenic acid desired in the product or the desired salt.
  • the desired content of pantothenic acid and/or the desired salt is in general in the range from 20 to 80 wt. % (based on the dry weight).
  • pantothenic acid can be determined with known chemical (Velisek; Chromatographic Science 60, 515-560 (1992)) or microbiological methods, such as e.g. the Lactobacillus plantarum test (DIFCO MANUAL, 10 th Edition, p. 1100-1102; Michigan, USA).
  • the hns gene from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the hns gene in E. coli K12 MG1655 (Accession Number AE000222, Blattner et al. (Science 277, 1453-1462 (1997)), PCR primers are synthesized (MWG Biotech, Ebersberg, Germany). (SEQ ID No.1) Primer hns 5′: 5′-GTTTGAGATTACTACAATGAGCG-3′ (SEQ ID No.2) Primer hns 3′: 5′-GCAAGTGCAATCTACAAAAAG-3′
  • the chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturer's instructions with “Qiagen Genomic-tips 100/G” (QIAGEN, Hilden, Germany). A DNA fragment approx. 450 bp in size can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A guide to methods and applications, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA).
  • the PCR product is ligated according to the manufacturer's instructions with the vector pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The Netherlands) and transformed into the E. coli strain TOP10. Selection of plasmid-carrying cells takes place on LB agar, to which 50 ⁇ g/ml kanamycin are added.
  • the vector pCR-Blunt II-TOPO-hns is cleaved with the restriction enzymes HindIII and XbaI and, after separation in 0.8% agarose gel, the hns fragment is isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany).
  • the vector pTrc99A (Amersham Biosciences, Freiburg, Germany) is cleaved with the enzymes HindIII and XbaI, subsequently dephosphorylated with alkaline phosphatase according to the manufacturer's instructions (Amersham Biosciences, Freiburg, Germany) and ligated with the hns fragment isolated.
  • coli strain XL1-Blue MRF' (Stratagene, La Jolla, USA) is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 ⁇ g/ml ampicillin is added. Successful cloning can be demonstrated after plasmid DNA isolation by control cleavage with the enzymes HpaI and SmaI as well as StyI.
  • the plasmid is called pTrc99Ahns (FIG. 1).
  • a selected ⁇ -hydroxyaspartic acid-resistant individual colony is then incubated on minimal agar, which comprises 2 g/L glucose and 0.2 g/L O-methylthreonine, at 37° C.
  • minimal agar which comprises 2 g/L glucose and 0.2 g/L O-methylthreonine
  • FE6-1 is resistant to L-valines, ⁇ -ketoisovaleric acid, ⁇ -hydroxyaspartic acid and O-methylthreonine.
  • DSM13721 Deutsche Sammlung für Mikroorganismen und Zellkulturen
  • the plasmids pTrc99A and pTrc99Ahns are transformed individually into the strain FE6-1 and plasmid-carrying cells are selected on LB agar, to which 50 ⁇ g/ml ampicillin are added.
  • the strains obtained are called FE6-1/pTrc99A and FE6-1/pTrc99Ahns.
  • pantothenate production of the E. coli strains FE6-1/pTrc99A and FE6-1/pTrc99Ahns is checked in batch cultures of 10 ml contained in 100 ml conical flasks.
  • the concentration of the D-pantothenate formed is then determined in the culture supernatant centrifuged off by means of High Performance Liquid Chromatography [column: Reversed Phase MZ-Aqua Perfect (diameter 4,6 mm), mobile Phase 25 mM acetate buffer with 10% methanol, flow rate 1 ml/min, RI detector].

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
US10/167,647 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof Abandoned US20030119151A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128780A DE10128780A1 (de) 2001-06-13 2001-06-13 Verfahren zur fermentativen Herstellung von D-Pantothensäure und/oder deren Salzen
DE10128780.1 2001-06-13

Publications (1)

Publication Number Publication Date
US20030119151A1 true US20030119151A1 (en) 2003-06-26

Family

ID=7688209

Family Applications (10)

Application Number Title Priority Date Filing Date
US10/167,650 Abandoned US20030092138A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,428 Abandoned US20030064485A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,648 Abandoned US20030124682A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,656 Abandoned US20030100081A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,647 Abandoned US20030119151A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,457 Expired - Lifetime US6913912B2 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,580 Abandoned US20030104583A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,427 Abandoned US20030124681A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,645 Abandoned US20040259214A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,646 Abandoned US20030109012A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/167,650 Abandoned US20030092138A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,428 Abandoned US20030064485A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,648 Abandoned US20030124682A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,656 Abandoned US20030100081A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/167,457 Expired - Lifetime US6913912B2 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,580 Abandoned US20030104583A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,427 Abandoned US20030124681A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,645 Abandoned US20040259214A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof
US10/167,646 Abandoned US20030109012A1 (en) 2001-06-13 2002-06-13 Process for the preparation of D-pantothenic acid and/or salts thereof

Country Status (7)

Country Link
US (10) US20030092138A1 (de)
EP (4) EP1395662B1 (de)
AT (3) ATE305973T1 (de)
AU (10) AU2002312930A1 (de)
DE (4) DE10128780A1 (de)
DK (3) DK1395662T3 (de)
WO (10) WO2002101065A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232081B2 (en) * 1999-09-21 2012-07-31 Basf Se Methods and microorganisms for production of panto-compounds
DE10128780A1 (de) * 2001-06-13 2002-12-19 Degussa Verfahren zur fermentativen Herstellung von D-Pantothensäure und/oder deren Salzen
DE60235810D1 (de) * 2001-07-06 2010-05-12 Evonik Degussa Gmbh Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämme mit verstärkter expression des fba-gens
EP1483393A1 (de) * 2002-03-13 2004-12-08 Degussa AG Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae
WO2003076637A1 (en) 2002-03-13 2003-09-18 Degussa Ag Process for the preparation of l-amino acids using strains of the family enterobacteriaceae
DE102004029639A1 (de) * 2003-08-12 2005-03-24 Degussa Ag Verfahren zur Herstellung von L-Threonin
CN112126666B (zh) * 2020-09-22 2022-04-08 廊坊梅花生物技术开发有限公司 核苷高产菌及其构建方法与应用
CN112195143B (zh) * 2020-09-24 2022-10-14 浙江工业大学 一种用于发酵法生产d-泛酸的菌株及发酵法生产d-泛酸的方法
CN114657221A (zh) * 2020-12-22 2022-06-24 安徽华恒生物科技股份有限公司 一种d-泛酸的制备方法
KR102589135B1 (ko) * 2021-05-10 2023-10-12 씨제이제일제당 (주) 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0493060A3 (en) * 1990-12-25 1993-04-14 Takeda Chemical Industries, Ltd. Production method of d-pantothenic acid and plasmids and microorganisms thereof
JP3058504B2 (ja) * 1992-03-30 2000-07-04 マルカン酢株式会社 アルデヒド脱水素酵素
JP3710497B2 (ja) * 1992-09-25 2005-10-26 ビーエーエスエフ アクチェンゲゼルシャフト Ｄ−パント酸、ｄ−パントテン酸およびそれらの塩の製造法
CN1074791C (zh) * 1995-04-21 2001-11-14 Basf公司 生产d－泛酸钙的方法
DE19846499A1 (de) * 1998-10-09 2000-04-20 Degussa Verfahren zur Herstellung von Pantothensäure durch Verstärkung von für Ketopantoat-Reduktase kodierenden Nukleotidsequenzen
US6238714B1 (en) * 1999-05-05 2001-05-29 Degussa-Huls Ag Feedstuff additive which contains D-pantothenic acid and/or its salts and a process for the preparation thereof
DK1050219T3 (da) * 1999-05-05 2003-03-17 Degussa Foderstofadditiver indeholdende D-pantothensyre og/eller salte deraf og fremgangsmåder til fremstilling deraf
US6319528B1 (en) * 1999-05-05 2001-11-20 Degussa Aktiengesellschaft Feedstuff additive which contains D-pantothenic acid and/or its salts and a process for the preparation thereof
CA2383865A1 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
MXPA01012842A (es) * 1999-06-25 2002-07-09 Basf Ag Genes de corynebacterium glutamicum que codifican proteinas involucradas en el metabolismo del carbono y la produccion de energia.
JP2003144161A (ja) * 1999-07-02 2003-05-20 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
DE19958160A1 (de) * 1999-12-02 2001-06-07 Degussa Neue für das gpm-Gen codierende Nukleotidsequenzen
DE10128780A1 (de) * 2001-06-13 2002-12-19 Degussa Verfahren zur fermentativen Herstellung von D-Pantothensäure und/oder deren Salzen

Also Published As

Publication number Publication date
WO2002101050A3 (en) 2003-10-16
WO2002101064A2 (en) 2002-12-19
WO2002101055A3 (en) 2003-07-17
AU2002314099A1 (en) 2002-12-23
WO2002101062A2 (en) 2002-12-19
DE60206622T2 (de) 2006-06-22
DK1395661T3 (da) 2006-02-20
EP1395661B1 (de) 2005-10-05
DE60206499T2 (de) 2006-06-22
AU2002302624A1 (en) 2002-12-23
WO2002101068A2 (en) 2002-12-19
US6913912B2 (en) 2005-07-05
AU2002316916A1 (en) 2002-12-23
WO2002101050A2 (en) 2002-12-19
AU2002302623A1 (en) 2002-12-23
DE60206498D1 (de) 2006-02-16
US20030124682A1 (en) 2003-07-03
WO2002101066A3 (en) 2003-07-17
US20030109012A1 (en) 2003-06-12
AU2002314098A1 (en) 2002-12-23
US20030092138A1 (en) 2003-05-15
ATE305974T1 (de) 2005-10-15
ATE306552T1 (de) 2005-10-15
US20030087404A1 (en) 2003-05-08
EP1395660A2 (de) 2004-03-10
WO2002101066A2 (en) 2002-12-19
AU2002314100A1 (en) 2002-12-23
WO2002101055A2 (en) 2002-12-19
WO2002101054A3 (en) 2003-08-21
WO2002101065A3 (en) 2003-12-18
EP1395662B1 (de) 2005-10-05
WO2002101067A3 (en) 2003-07-17
WO2002101064A3 (en) 2003-12-11
US20030100081A1 (en) 2003-05-29
US20030064485A1 (en) 2003-04-03
AU2002345769A1 (en) 2002-12-23
US20040259214A1 (en) 2004-12-23
ATE305973T1 (de) 2005-10-15
WO2002101068A3 (en) 2003-09-04
EP1395661A2 (de) 2004-03-10
EP1395660B1 (de) 2005-10-12
US20030104583A1 (en) 2003-06-05
EP1395663A2 (de) 2004-03-10
US20030124681A1 (en) 2003-07-03
EP1395662A2 (de) 2004-03-10
DE10128780A1 (de) 2002-12-19
WO2002101067A2 (en) 2002-12-19
WO2002101062A3 (en) 2003-09-04
DK1395662T3 (da) 2006-02-20
DE60206498T2 (de) 2006-07-06
DE60206622D1 (de) 2006-02-23
WO2002101063A2 (en) 2002-12-19
DK1395660T3 (da) 2006-02-20
DE60206499D1 (de) 2006-02-16
AU2002316917A1 (en) 2002-12-23
WO2002101054A2 (en) 2002-12-19
AU2002302625A1 (en) 2002-12-23
WO2002101065A2 (en) 2002-12-19
AU2002312930A1 (en) 2002-12-23
WO2002101063A3 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US6913912B2 (en) Process for the preparation of D-pantothenic acid and/or salts thereof
US20020173010A1 (en) Process for preparation of D-pantothenic acid and/or salts thereof
US6689592B2 (en) Process for the enzymatic production of D-pantothenic acid and/or its salts
US6682915B2 (en) Process for the fermentative preparation of D-pantothenic acid and/or its salts
US6686183B2 (en) Process for the fermentative preparation of D-pantothenic acid and/or its salts
US7338792B2 (en) Process for the preparation of D-pantothenic acid and/or salts thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEGUSSA AS, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HERMANN, THOMAS;WITTECK, BIRGIT;RIEPING, MECHTHILD;REEL/FRAME:013370/0345;SIGNING DATES FROM 20020829 TO 20020830

AS Assignment

Owner name: DEGUSSA AG, GERMANY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME. DOCUMENT PREVIOUSLY RECORDED AT REEL 013370 FRAME 0345;ASSIGNORS:HERMANN, THOMAS;WITTECK, BIRGIT;RIEPING, MECHTHILD;REEL/FRAME:013736/0853;SIGNING DATES FROM 20020829 TO 20020830

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION